EARNINGS PER SHARE

12 Months Ended

Mar. 28, 2020

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.



(In thousands, except per share amounts)	2020		2019		2018
Basic EPS
Net income	$	76,526	$	55,019	$	45,572
Weighted average shares	50,692		51,533		52,755
Basic income per share	$	1.51	$	1.07	$	0.86
Diluted EPS
Net income	$	76,526	$	55,019	$	45,572
Basic weighted average shares	50,692		51,533		52,755
Net effect of common stock equivalents	1,123		1,409		746
Diluted weighted average shares	51,815		52,942		53,501
Diluted income per share	$	1.48	$	1.04	$	0.85

Basic earnings per share is calculated using the Company's weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method. For fiscal 2020, 2019 and 2018, weighted average shares outstanding, assuming dilution, excludes the impact of 0.2 million, 0.2 million and 0.4 million anti-dilutive shares, respectively.

Share Repurchase Plan

In May 2019, the Company's Board of Directors authorized the repurchase of up to $500 million of Haemonetics common shares over the next two years. In July 2019, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement ("ASR") entered into with Citibank N.A. ("Citibank") in June 2019. The total number of shares repurchased under the ASR was 0.6 million at an average price per share upon final settlement of $116.33. In October 2019, the Company completed a $50.0 million repurchase of its common stock pursuant to an ASR entered into with Morgan Stanley & Co. LLC ("Morgan Stanley") in September 2019. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of $124.37. In January 2020, the Company completed an additional $50.0 million repurchase of its common stock pursuant to an ASR entered into with Bank of America, N.A. ("Bank of America") in December 2019. The total number of shares repurchased under the ASR was 0.4 million at an average price per share upon final settlement of $114.73. As of March 28, 2020, the total remaining authorization for repurchases of the Company's common stock under the share repurchase program was $325.0 million.